Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Fortress Biotech, Inc.'s quarterly P/E stands at 8.4x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.27 | 8.41 | 1.03 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.65 | 1.74 | 0.84 | 0.79 | 0.68 | 0.49 | 0.53 | 0.66 | 0.29 | 0.23 | 0.88 | 1.68 | 0.91 |
| — | +255.8% | +60.7% | +19.3% | +130.7% | +108.0% | -39.9% | -60.8% | -67.7% | -79.8% | -11.3% | +36.8% | -68.1% | |
| P/B Ratio | — | 1.88 | 1.48 | 1.27 | — | — | — | — | 14.80 | — | — | 4.22 | 1.20 |
| — | — | — | — | — | — | — | — | +1138.1% | — | — | +594.6% | +29.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 2.32 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Fortress Biotech, Inc.'s operating margin was -38.6% in Q3 2025, up 183.6 pp QoQ and up 112.4 pp YoY. The trailing four-quarter average of -152.9% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 5.5% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.8% | 67.4% | 69.9% | 63.5% | 61.6% | 63.9% | 56.1% | 53.9% | 69.8% | 81.5% | 55.3% | 48.1% | 47.9% |
| — | +5.5% | +24.6% | +17.8% | -11.8% | -21.6% | +1.4% | +12.1% | +45.7% | +44.7% | -7.1% | -26.8% | +9.6% | |
| Operating Margin | -191.4% | -38.6% | -222.2% | -169.9% | -180.9% | -151.0% | -186.5% | -280.6% | -98.3% | -39.6% | -288.2% | -473.6% | -333.1% |
| — | +74.4% | -19.1% | +39.5% | -83.9% | -281.5% | +35.3% | +40.7% | +70.5% | +87.1% | -6.9% | -139.7% | +1.8% | |
| Net Margin | -79.8% | 33.2% | 94.4% | -80.6% | -44.7% | -88.0% | -73.5% | -118.3% | -46.5% | -14.5% | -142.5% | -173.3% | -164.3% |
| — | +137.7% | +228.4% | +31.9% | +3.8% | -505.9% | +48.4% | +31.7% | +71.7% | +89.3% | -26.0% | -163.1% | +4.9% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | 11.4% | 44.3% | -68.6% | — | — | — | — | -584.7% | — | -1282.7% | -61.7% | -35.6% |
| — | — | — | — | — | — | — | — | -1542.2% | — | -10149.4% | -720.9% | -147.2% | |
| ROA | -29.5% | 3.4% | 9.2% | -6.6% | -5.0% | -9.4% | -7.1% | -9.3% | -5.8% | -3.0% | -11.2% | -7.7% | -8.7% |
| — | +136.3% | +229.9% | +29.2% | +14.5% | -209.7% | +36.7% | -20.2% | +33.1% | +53.5% | -101.6% | -97.1% | -11.1% | |
| ROIC | -629.4% | -12.9% | -114.9% | -103.2% | -241.4% | — | — | -673.9% | -159.0% | — | — | — | -468.0% |
| — | — | — | +84.7% | -51.8% | — | — | — | +66.0% | — | — | — | -98.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 78.6% YoY to 2.19x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 1.05 | 1.85 | 2.29 | — | — | — | — | 55.82 | — | — | 6.19 | 2.55 |
| — | — | — | — | — | — | — | — | +2092.9% | — | — | +909.3% | +666.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.27 | 2.19 | 1.92 | 1.72 | 1.27 | 1.23 | 1.37 | 1.33 | 1.38 | 1.00 | 0.99 | 1.56 | 1.80 |
| — | +78.6% | +40.2% | +29.6% | -8.2% | +22.1% | +38.0% | -15.0% | -23.6% | -58.6% | -65.2% | -52.7% | -47.4% | |
| Quick Ratio | 1.06 | 1.97 | 1.70 | 1.55 | 1.06 | 1.06 | 1.24 | 1.21 | 1.26 | 0.89 | 0.90 | 1.46 | 1.69 |
| — | +86.2% | +36.6% | +28.5% | -15.5% | +18.8% | +38.2% | -17.3% | -25.7% | -61.0% | -66.7% | -53.7% | -49.2% | |
| Interest Coverage | -11.12 | -2.82 | -14.48 | -7.96 | -10.54 | -3.56 | -13.10 | -14.05 | -9.52 | -5.43 | -13.81 | -13.70 | -11.51 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonFortress Biotech, Inc.'s current P/E is -1.3x. The average P/E over the last 2 quarters is 4.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Fortress Biotech, Inc.'s current operating margin is -191.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Fortress Biotech, Inc.'s business trajectory between earnings reports.